Insider Trading May 11, 2026 07:04 PM

Ormat Technologies Director Executes Stock Sale Following RSU Vesting

Dafna Sharir liquidates 883 shares under a pre-arranged trading plan amidst strong quarterly performance and upward price target revisions.

By Sofia Navarro ORA

Dafna Sharir, a member of the board of directors at Ormat Technologies, Inc. (NYSE: ORA), has completed a sale of common stock totaling $108,114. The transaction took place on May 11, 2026, when 883 shares were sold at a price point of $122.44 per share. This movement in equity follows the recent vesting of Restricted Stock Units (RSUs) earlier in the month.

Ormat Technologies Director Executes Stock Sale Following RSU Vesting
ORA

Key Points

  • Director Dafna Sharir sold 883 shares at $122.44 per share via a 10b5-1 plan.
  • Ormat reported Q1 2026 adjusted EPS of $1.30, beating the $0.91 forecast.
  • Oppenheimer raised its price target for ORA to $144.

Ormat Technologies, Inc. (NYSE: ORA) recently saw insider activity from one of its directors. On May 11, 2026, Dafna Sharir sold 883 shares of the company's common stock. The shares were liquidated at a price of $122.44 each, which brought the total value of the transaction to $108,114.

The sale was closely tied to a prior vesting event. On May 7, 2026, 1,766 Restricted Stock Units (RSUs) vested for Ms. Sharir. These RSUs were granted under terms where they would convert into an equivalent number of common shares upon reaching their one-year anniversary from the date of the grant. The sale of 883 shares occurred following this conversion of vested units into common stock.

This specific transaction was not an impromptu market move but was conducted under a pre-arranged 10b5-1 trading plan. Ms. Sharir had originally adopted this plan on November 18, 2025, to govern future trades. Following the completion of this sale, Ms. Sharir maintains a direct holding of 3,140 shares of Ormat Technologies common stock.


Market Context and Financial Performance

The timing of this transaction occurs against a backdrop of significant stock movement and recent financial reporting. Ormat Technologies' stock has seen substantial growth, trading at $123.63 at the time of the report, which represents a 66% increase over the previous year. Despite this momentum, some analysis suggests that the company may be appearing overvalued at its current trading levels.

The company's recent fundamental data remains robust. In its first-quarter 2026 financial results, Ormat Technologies reported figures that notably exceeded market expectations. The company posted adjusted earnings per share (EPS) of $1.30, which was a significant surprise compared to the projected $0.91, marking a 42.86% beat. Additionally, quarterly revenue reached $403.9 million, outperforming forecasts by 15.74%. These metrics have contributed to heightened investor confidence.

Looking forward, Ormat Technologies has maintained its full-year 2026 guidance, signaling a positive outlook for the remainder of the year. Reflecting this optimism, Oppenheimer recently adjusted its price target for the company upward from $136 to $144, while retaining an Outperform rating.


Key Insights

  • Insider Liquidity: The sale was executed through a structured 10b5-1 plan, providing clarity on the transaction's timing and intent.
  • Strong Earnings Momentum: Recent Q1 2026 results showed significant beats in both revenue and adjusted EPS, impacting the energy and utility sectors.
  • Positive Analyst Sentiment: Price target increases from firms like Oppenheimer indicate a bullish outlook on the company's valuation trajectory within the renewable energy infrastructure space.

Risks and Uncertainties

  • Valuation Concerns: Despite strong stock performance, there are indications that the current price levels may reflect an overvaluation, which could impact growth-oriented investors in the energy sector.
  • Market Volatility: While the stock has gained 66% over the last year, such rapid appreciation can lead to increased sensitivity to market shifts.

Risks

  • Potential overvaluation despite strong momentum according to analysis.
  • Dependence on maintaining positive full-year 2026 guidance.

More from Insider Trading

Edwards Lifesciences CEO Executes Multi-Million Dollar Share Sale via Pre-Set Trading Plan May 12, 2026 Covista CFO Executes $1.26 Million Stock Sale via Pre-Scheduled Trading Plan May 12, 2026 Covista Executive Executes Planned Share Sale Amidst Corporate Growth and Financial Restructuring May 12, 2026 Covista Executive Executes $1.22 Million Stock Sale Under Pre-Planned Trading Program May 12, 2026 Ameriprise Financial Director Executes Stock Sale Amid Strong Earnings Performance May 12, 2026